News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Kunshan RiboQuark Raises $7.5 Million For siRNA Projects


1/10/2014 3:53:59 PM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

by Richard Daverman, PhD

January 10, 2014 -- Kunshan RiboQuark Pharma, a siRNA joint venture formed by Suzhou Ribo Life Science and Quark Pharma of California, raised almost 45 million RMB ($7.5 million) in a series A round. The financing was led by BVCF, formerly known as BioVeda China. RiboQuark will use the money to further clinical development of QPI-1007, a siRNA ocular neuroprotectant developed by Quark for which the JV owns China rights. More details....

Help employers find you! Check out all the jobs and post your resume.

Read at ChinaBio Today


comments powered by Disqus
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES